Bioengineered Protein Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Bioengineered Protein Drugs Market: By Drug Type (Vaccines, Peptide hormones, Blood Products, Monoclonal antibodies, Recombinant protein drugs, Replacement proteins, Peptide antibiotics, Therapeutic enzymes, Cytokines), By Technology (Bioreactors and microbial cell fermentation, Genetically modified organisms, Fractionation, Pharming, Others), By Application (Diabetes, Heart diseases, Neurodegenerative diseases, Respiratory diseases, Infectious diseases, Congenital diseases, Others), By Drug delivery (Traditional methods, Novel Methods), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global bioengineered protein drugs market size valued 150.5 billion in 2020, growing at a CAGR of 3.4% during the forecast period 2021-2027. Bioengineered proteins are formulated as the fundamental participants in the biological process. They are target specific and have lesser side effects which leads to higher acceptance when compared to that of a small molecule. Bioengineered Protein Drugs Market act as the powerful therapeutic agents. They include a wide range of products such as monoclonal antibodies, cytokines, growth factors, and many. Due to various factors such as bio-reactivity, safety, and success rate bioengineered proteins are gaining popularity all across the healthcare industry.

Bioengineered Protein Drugs Market

MARKET SUMMARY
-
3.4% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 3.4%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Bioengineered Protein Drugs Market

  • The report on global bioengineered protein drugs market gives historical, current and future market sizes (US$ Mn) based on drug type, technology, application, by drug delivery and geographical regions
  • bioengineered protein drugs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Abbott Laboratories
  • Amgen
  • KEDRION BIOPHARMA
  • Merck & Co., Inc.
  • Allergan
Bioengineered Protein Drugs Market

Drivers And Restraints

Increase in prevalence of chronic diseases such as diabetics, cancer etc. is one of the major factor responsible for the growth of the bioengineered protein drugs market. According to the WHO, the diabetic population is expected to grow by 366 million by 2030. The technological advancements in the drug delivery system and noticeable manufacturing developments in the biopharmaceutical industry is likely to drive the growth of the bioengineered protein drugs market over the forecast period. The minimal side effects of the bioengineered protein drugs also boosting the growth of the market. However, the higher cost of the drugs is likely to hamper the growth of the market.


North-America got significant share

Bioengineered Protein Drugs Market

Geographically, global bioengineered protein drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America bioengineered protein drugs market holding larger revenue share when compared with that of the other markets. The growing technological advanced products, developed research sector are driving the growth of the bioengineered protein drugs market in North America region. The growing awareness among the people about chronic diseases and the higher adoption of the new drugs is also responsible for the growth of the market in this region. The Asia Pacific region expected to grow at significant rate owing to expansion of the biopharmaceutical industries in the region. The developing economic scenario is showing scope for the development of R&D activities in this region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In August 2017, Kedrion Biopharma and Kamada Ltd. has received U.S. Food and Drug Administration (FDA) approval for KEDRAB™ [rabies immune globulin (Human)], for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal.

Key

Key Findings of the Report

Bioengineered Protein Drugs Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories (U.S)
  • Amgen (U.S)
  • KEDRION BIOPHARMA (U.S)
  • Merck & Co., Inc. (U.S)
  • Allergan (Ireland)
  • Eli Lilly and Company (U.S)
  • Johnson & Johnson (U.S)
  • Panacea Biotec (India)
  • GlaxoSmithKline plc (U.K)
  • Hoffmann-La Roche (Switzerland)

Description

The global bioengineered protein drugs market size valued 150.5 billion in 2020, growing at a CAGR of 3.4% during the forecast period 2021-2027. Bioengineered proteins are formulated as the fundamental participants in the biological process. They are target specific and have lesser side effects which leads to higher acceptance when compared to that of a small molecule. Bioengineered Protein Drugs Market act as the powerful therapeutic agents. They include a wide range of products such as monoclonal antibodies, cytokines, growth factors, and many. Due to various factors such as bio-reactivity, safety, and success rate bioengineered proteins are gaining popularity all across the healthcare industry.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX